Bird & Bird advises uMotif on their latest $25.5m investment from a fund managed by Athyrium Capital Management
Contacts
Partner
UK
I'm a partner in our International Corporate Group in London. I specialise in venture capital and private M&A, focusing on the financing, acquisition and sale of high-growth organisations.
Partner
UK
I am a partner in the Corporate team and am based in our London office. I advise clients on a range of corporate transactions with a particular focus on Venture Capital and Mergers & Acquisitions, predominantly involving technology companies.
International law firm Bird & Bird advises uMotif on their latest $25.5m investment from a fund managed by Athyrium Capital Management.
uMotif's mission is to put patients at the centre of clinical research. uMotif’s software is designed to provide pharmaceutical, biotech, medtech and CRO clients with the most engaging patient data capture experience. By focusing on high quality design and modern cloud-native software, uMotif delivers high rates of data capture, patient retention, data quality and delivery speed - ultimately helping achieve faster, better trials. The new funding will support continued scale up of uMotif’s unique patient-first software platform for clinical research.
Having deployed their software in over 30 countries globally including China and Japan, the uMotif platform powers all study designs, in all research settings. As study designs get more complex, with more burden placed on patients, the uMotif platform helps to simplify studies. uMotif has worked with many of the world’s top pharma, biotech, Contract Research Organisations (CROs) including AstraZeneca, Abbvie and Syneos.
The company continues to be supported by its existing investors AlbionVC and DNV, that led a Series A investment round in 2020. The new investment of $25.5m from a fund managed by Athyrium Capital Management, supports further international expansion and continued development of world-leading technologies, including unique and patent-protected solutions for pain, clinical outcome and symptom tracking. This growth takes place alongside a continued focus on developing the industry’s most patient-centric technology.
The Bird & Bird team was led by Mark Rundall (partner, Corporate) and Samrad Nazer (partner, Finance) alongside Zoe Feller (partner, Tax), Harry Osborne (associate, Finance), Adam Meisels (associate, Corporate) and Emily Patel (associate, Tax).
Mark Rundall and Samrad Nazer, partners at Bird & Bird, says: “We are delighted to work with uMotif on their latest funding round, supporting them on its significant scale-up journey. This transaction is a great example of our work within the disruptive tech space, and we look forward to supporting uMotif in the future.”